A just-completed merger between Phidea and Marvin Research, two contract research organisations (CROs) based in Milan, Italy, will position the companies for growth and expansion into global markets, Phidea says.

The new company, Phidea Marvin S.r.l, will have its legal and operating headquarters in Milan while continuing to run offices in Madrid, Spain. Phidea established a Spanish subsidiary, Phidea Spain, in the capital in 1991. Phidea Marvin will offer services spanning the design and management of pan-European clinical trials (Phases I to III) and post-marketing studies (Phase IV). The terms of the merger were not disclosed.

Available services will include protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing, as well as observational and epidemiological studies. Areas of speciality will be cardiovascular conditions, the central nervous system, gastroenterology, oncology, rheumatology and infectious diseases.

Phidea was founded in 1982 and Marvin Research in 1999. According to Dr Vincenzo Cocuzza, chairman and chief executive officer of the merged Phidea Marvin, the combination further broadens Phidea’s client base and “provides the necessary platform” for growth. “We have a compelling strategy to expand operations into global markets and especially the United States, and will continue to look for strategic opportunities that allow us to realise our goals,” Cocuzza commented.

Specifically, he said, the merger added to Phidea a partner with a strong market position and reputation in particular therapeutic areas; brought on board new multinational customers; reduced costs; and boosted the overall size of the organisation, allowing it to conduct “even larger” studies.

“We also believe that the Marvin and Phidea teams have built an impressive portfolio of accomplishments and will work together to become a leader in the CRO sector,” Cocuzza added.